EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Human-mouse chimeric 131I-labeled anti-CD20 monoclonal antibody in relapsed non-Hodgkins lymphoma Dosimetry and radioimmunotherapy



Human-mouse chimeric 131I-labeled anti-CD20 monoclonal antibody in relapsed non-Hodgkins lymphoma Dosimetry and radioimmunotherapy



Journal of Nuclear Medicine 41(5 Suppl ): 268P




(PDF emailed within 1 workday: $29.90)

Accession: 035056034

Download citation: RISBibTeXText



Related references

Radioimmunotherapy with 131I anti-CD20 chimeric monoclonal antibody for relapsed or refractory non-Hodgkins lymphoma. Journal of Nuclear Medicine 43(5 Supplement): 115P-116P, 2002

Radioimmunotherapy of refractory non-Hodgkins lymphoma with 131I-labeled chimeric 81C6 anti-tenascin monoclonal antibody Dosimetry study. Journal of Nuclear Medicine 43(5 Supplement): 313P, 2002

131I-Anti CD20 radioimmunotherapy of relapsed or refractory non-Hodgkins lymphoma: a phase II clinical trial of a nonmyeloablative dose regimen of chimeric rituximab radiolabeled in a hospital. Cancer BioTherapy & Radiopharmaceuticals 18(4): 513-524, 2003

High-dose, myeloablative radioimmunotherapy of mantle cell non-Hodgkins lymphoma with the 131I-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support Results of a pilot study. Cancer Biotherapy & Radiopharmaceuticals 15(4): 408, 2000

Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with zevalin, a 90Y-labeled anti-CD20 monoclonal antibody. Clinical Cancer Research 5(10 Suppl): 3281s-3286s, 1999

Radioimmunotherapy of relapsed refractory non-Hodgkins lymphoma with 90Y-labeled humanized LL2 anti-CD22 monoclonal antibody. Acta Haematologica (Basel) 103(Supplement 1): 55, July, 2000

Successful treatment with a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) for a patient with relapsed mantle cell lymphoma who developed a human anti-chimeric antibody. International Journal of Hematology 74(1): 70-75, 2001

High-dose radioimmunotherapy of mantle cell lymphoma with the 131I-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support. Journal of Nuclear Medicine 42(5 Supplement): 156P-157P, 2001

Phase I study of IDEC-Y2B8 90-yttrium labeled anti-CD20 monoclonal antibody therapy of relapsed Non-Hodgkins lymphoma. Blood 86(10 SUPPL 1): 55A, 1995

Interim results of a phase I/II radioimmunotherapy trial in relapsed/refractory non-Hodgkins lymphoma patients given 90Y-labeled anti-CD22 humanized monoclonal antibody, epratuzumab. Blood 98(11 Part 1): 611a, November 16, 2001

Y-90 anti-CD20 monoclonal antibody dosimetry calculated from In-111 anti-CD20 in patients with low and intermediate grade B-cell non-Hodgkins lymphoma. Journal of Nuclear Medicine 38(5 SUPPL ): 251P, 1997

Updated results of radioimmunotherapy of relapsed/refractory non-Hodgkins lymphoma with conventional and stem cell supported doses of 90Y-labeled humanized LL2 anti-CD22 monoclonal antibody. Cancer Biotherapy & Radiopharmaceuticals 15(4): 408, 2000

Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma. Clinical Cancer Research 5(10 Suppl): 3292s-3303s, 1999

Treatment of relapsed B-cell non Hodgkins lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies and G-CSF Final report on safety and efficacy. Blood 96(11 Part 1): 732a-733a, November 16, 2000

Radioimmunotherapy of low-grade B-cell lymphoma with ( 90)Y-labeled anti-CD20 monoclonal antibody (Zevalin). Nihon Hoshasen Gijutsu Gakkai Zasshi 65(3): 367-371, 2009